Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

DNTH

Dianthus Therapeutics Inc

Nov 14 • 04:00PM ET

40.85

+5.35 15.07 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM VXF XBI SCHA IWN VTWO AVSC IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.49	Insider Own	24.06%	Shs Outstand	42.85M	Perf Week	12.60%
Market Cap	1.75B	Forward P/E	-	EPS next Y	-3.65	Insider Trans	-2.06%	Shs Float	32.56M	Perf Month	13.47%
Enterprise Value	1.35B	PEG	-	EPS next Q	-1.07	Inst Own	95.91%	Short Float	12.37%	Perf Quarter	94.90%
Income	-126.34M	P/S	568.67	EPS this Y	-45.75%	Inst Trans	4.15%	Short Ratio	5.71	Perf Half Y	107.47%
Sales	3.08M	P/B	3.20	EPS next Y	1.75%	ROA	-27.12%	Short Interest	4.03M	Perf YTD	87.39%
Book/sh	12.75	P/C	4.35	EPS next 5Y	-17.45%	ROE	-28.57%	52W High	40.16 1.72%	Perf Year	47.58%
Cash/sh	9.39	P/FCF	-	EPS past 3/5Y	50.25% 40.14%	ROIC	-23.08%	52W Low	13.36 205.65%	Perf 3Y	134.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.71%	Volatility	9.09% 6.17%	Perf 5Y	-58.15%
Dividend TTM	-	EV/Sales	438.36	EPS Y/Y TTM	-39.78%	Oper. Margin	-4558.41%	ATR (14)	2.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.35	Sales Y/Y TTM	-42.64%	Profit Margin	-4104.78%	RSI (14)	65.57	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	17.35	EPS Q/Q	-32.30%	SMA20	16.41%	Beta	1.58	Target Price	67.42
Payout	-	Debt/Eq	0.00	Sales Q/Q	-81.77%	SMA50	13.65%	Rel Volume	2.22	Prev Close	35.50
Employees	78	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	SMA200	68.15%	Avg Volume	706.10K	Price	40.85
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.82% -31.25%	Trades		Volume	1,570,447	Change	15.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-25	Initiated	Truist	Buy	$56
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21

Show Previous Ratings

Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.00%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Dianthus Therapeutics to Participate in Four Investor Conferences During November (GlobeNewswire)
Oct-30-25 10:00AM	Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
03:30PM	Loading…
Oct-29-25 03:30PM	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire)
Oct-16-25 07:00AM	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases (GlobeNewswire)
Oct-02-25 08:00AM	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting (GlobeNewswire) -5.14%
Sep-30-25 11:50AM	Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target (Insider Monkey)
Sep-19-25 03:26PM	Dianthus, Opendoor, and More Stocks See Action From Activist Investors (Barrons.com) -5.45%
Sep-11-25 04:07PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-09-25 10:35PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering (GlobeNewswire) +11.86% +6.55%
10:57AM	Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential (Insider Monkey)
07:15AM	Dianthus to take gMG mAb to Phase III after mid-stage win (Clinical Trials Arena)
Sep-08-25 04:00PM	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering (GlobeNewswire) +20.00%
02:45PM	Loading…
02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:21PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
07:00AM	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile (GlobeNewswire)
Sep-07-25 06:25PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-13-25 04:04PM	The Oncology Institute Announces Changes to Board of Directors (GlobeNewswire)
Aug-07-25 05:20PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.08%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-06-25 06:45PM	Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
07:00AM	Loading…
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)
Apr-14-22 04:41PM	Stem cell startup cuts staff by 14% (American City Business Journals) -7.05% -14.29%
12:15PM	Magenta Therapeutics Trims R&D, Cuts Workforce (Benzinga)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Option Exercise	20.42	109,031	2,226,263	113,031	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Option Exercise	8.82	87,507	771,873	91,507	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Sale	38.14	109,031	4,158,442	4,000	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Sale	36.81	87,507	3,221,445	4,000	Nov 14 09:00 PM
SIMRAT RANDHAWA	Officer	Nov 13 '25	Proposed Sale	38.72	196,538	7,609,951		Nov 13 04:23 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Option Exercise	8.44	20,000	168,800	20,000	Sep 11 05:20 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Sale	35.00	20,000	700,000	0	Sep 11 05:20 PM
RYAN SAVITZ	Officer	Sep 09 '25	Proposed Sale	31.80	20,000	636,000		Sep 09 04:27 PM

Open in Screener

RVMD

Revolution Medicines Inc

Nov 14 • 04:00PM ET

67.75

+3.37 5.23 %

Healthcare • Biotechnology • USA • NASD

RVMD Revolution Medicines Inc daily Stock Chart

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI VB XBI VBK VXF IBB SCHA IWR SCHM IWD

Index	-	P/E	-	EPS (ttm)	-5.18	Insider Own	13.25%	Shs Outstand	189.71M	Perf Week	11.05%
Market Cap	13.10B	Forward P/E	-	EPS next Y	-6.31	Insider Trans	-1.09%	Shs Float	167.70M	Perf Month	36.37%
Enterprise Value	11.32B	PEG	-	EPS next Q	-1.59	Inst Own	90.18%	Short Float	10.75%	Perf Quarter	85.87%
Income	-960.98M	P/S	-	EPS this Y	-56.93%	Inst Trans	-1.90%	Short Ratio	8.19	Perf Half Y	71.35%
Sales	0.00M	P/B	8.05	EPS next Y	-12.37%	ROA	-47.87%	Short Interest	18.02M	Perf YTD	54.89%
Book/sh	8.42	P/C	6.78	EPS next 5Y	-16.43%	ROE	-60.76%	52W High	66.11 2.48%	Perf Year	14.19%
Cash/sh	9.99	P/FCF	-	EPS past 3/5Y	-11.66% -27.80%	ROIC	-55.26%	52W Low	29.17 132.26%	Perf 3Y	257.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.36% 4.10%	Perf 5Y	96.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.24%	Oper. Margin	-	ATR (14)	2.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	81.54	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.05	EPS Q/Q	-72.19%	SMA20	14.38%	Beta	0.96	Target Price	80.95
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	32.35%	Rel Volume	1.80	Prev Close	64.38
Employees	534	LT Debt/Eq	0.09	Earnings	Nov 05 AMC	SMA200	62.50%	Avg Volume	2.20M	Price	67.75
IPO	Feb 13, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.29% -100.00%	Trades		Volume	3,955,952	Change	5.23%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Initiated	RBC Capital Mkts	Outperform	$77
Oct-21-25	Initiated	Mizuho	Outperform	$90
Oct-16-25	Resumed	Stifel	Buy	$85
Sep-12-25	Resumed	Raymond James	Strong Buy	$72
Sep-05-25	Initiated	Truist	Buy	$99
Aug-19-25	Initiated	Piper Sandler	Overweight	$75
Aug-15-25	Initiated	Wells Fargo	Overweight	$67
Jul-15-25	Initiated	Goldman	Buy	$65
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31
Oct-21-22	Initiated	Oppenheimer	Outperform	$30

Show Previous Ratings

Nov-06-25 01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
12:05AM	Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 04:02PM	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-04-25 04:05PM	Revolution Medicines to Participate in November 2025 Investor Conferences (GlobeNewswire)
07:24AM	Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:42AM	Loading…
Nov-03-25 09:42AM	Boeing upgraded, Charter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 (GlobeNewswire)
Oct-27-25 08:00AM	Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer (GlobeNewswire) +6.44%
Oct-22-25 12:12PM	Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
Oct-19-25 03:21AM	Jim Cramer Says Revolution Medicines "Is a Speculative Situation" (Insider Monkey)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +8.90%
Oct-16-25 08:00PM	Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program (GlobeNewswire)
Oct-02-25 09:45AM	Revolution Medicines, Inc. (RVMD) Insider Sells Shares (Insider Monkey)
Sep-29-25 09:00AM	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer (GlobeNewswire)
06:15AM	Loading…
Sep-25-25 06:15AM	These 2 Stocks Could Be Prime Takeover Targets, According to Analysts (TipRanks)
Sep-12-25 09:00AM	Morning Movers: Kroger rises following second quarter results (TipRanks)
Sep-11-25 07:42AM	Revolutions daraxonrasib moves to Phase III after PDAC hat-trick (Clinical Trials Arena) +14.31%
Sep-10-25 04:02PM	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Sep-02-25 01:34AM	Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress (Insider Monkey)
Aug-28-25 11:49PM	Here's What the Wall Street Thinks About Revolution Medicines (RVMD) (Insider Monkey)
Aug-22-25 11:57PM	Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating (Insider Monkey)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-13-25 03:11PM	Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer (Insider Monkey)
Aug-06-25 04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:28AM	What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings (GuruFocus.com)
Jul-30-25 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 (GlobeNewswire)
Jul-28-25 09:55AM	Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade (Zacks)
Jul-24-25 04:00PM	Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor (GlobeNewswire)
04:00AM	Loading…
04:00AM	iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments (PR Newswire)
Jul-23-25 08:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (GlobeNewswire)
Jul-16-25 09:39AM	Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs (Insider Monkey)
Jul-09-25 08:00AM	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates (GlobeNewswire) +5.71%
12:55AM	Revolution Medicines' Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations (Insider Monkey)
Jul-06-25 04:00AM	Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors (Insider Monkey)
Jul-02-25 03:20AM	Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress (Insider Monkey)
Jun-30-25 08:00AM	Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors (Business Wire)
Jun-25-25 05:23AM	Revolution Medicines partners Royalty Pharma on $2bn funding (Pharmaceutical Technology)
Jun-24-25 07:00AM	Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers (GlobeNewswire)
Jun-23-25 09:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations (GlobeNewswire)
May-14-25 08:00AM	Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer (GlobeNewswire)
May-07-25 06:59PM	Revolution medicines outlines 2025 focus on RAS(ON) inhibitors in key cancer trials (Seeking Alpha) +11.29%
06:58PM	Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:02PM	Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Apr-30-25 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 (GlobeNewswire)
Apr-27-25 12:05PM	Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting (GlobeNewswire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha) +6.09%
Apr-09-25 05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire) +12.82%
Apr-08-25 06:29AM	Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (Seeking Alpha)
Apr-01-25 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-31-25 04:43PM	Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now (Insider Monkey) -5.33%
04:05PM	Revolution Medicines to Participate in April 2025 Investor Conferences (GlobeNewswire)
Mar-30-25 04:12PM	Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Feb-26-25 04:02PM	Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-24-25 04:05PM	Revolution Medicines to Participate in March 2025 Investor Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 (GlobeNewswire)
Jan-29-25 04:05PM	Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +5.25%
Jan-06-25 04:05PM	Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-24 04:05PM	Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-04-24 06:51AM	Revolution Medicines price target raised to $87 from $82 at Guggenheim (TipRanks)
Dec-03-24 10:38PM	Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.89%
Dec-02-24 04:31PM	Revolution Medicines Announces Commencement of Public Offering of Common Stock (GlobeNewswire) -10.46%
07:30AM	Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio (GlobeNewswire)
Nov-27-24 04:05PM	Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 (GlobeNewswire)
Nov-06-24 04:02PM	Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-05-24 09:00AM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-30-24 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 (GlobeNewswire) +5.94%
Oct-25-24 04:15AM	Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-23-24 06:00AM	Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Oct-21-24 04:05PM	Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) -5.31%
Oct-07-24 09:00AM	Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast (GlobeNewswire)
Aug-07-24 04:05PM	Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
Jul-31-24 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024 (GlobeNewswire)
Jul-11-24 12:00PM	Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-10-24 05:58AM	Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last? (Zacks)
Jul-08-24 04:05PM	Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 (GlobeNewswire) +5.46% +10.97%
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 04:05PM	Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-09-24 03:41PM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 09:58PM	RVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress (GlobeNewswire)
May-01-24 04:05PM	Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 (GlobeNewswire)
Apr-09-24 03:34PM	Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-08-24 11:36AM	Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins (GlobeNewswire)
Apr-04-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-28-24 04:05PM	Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 05:20PM	Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)
Feb-20-24 04:05PM	Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 (GlobeNewswire)
Feb-01-24 04:05PM	Revolution Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-17-24 09:55AM	Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High? (Zacks)
Jan-04-24 07:00AM	Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-09-23 09:10AM	Revolution Medicines Completes Acquisition of EQRx (GlobeNewswire) -5.48%
Nov-08-23 11:30AM	Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition (GlobeNewswire)
Nov-07-23 10:14AM	Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:50PM	Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:55PM	Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:05PM	Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress (GlobeNewswire)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Option Exercise	4.09	20,000	81,800	267,863	Nov 14 08:45 PM
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Sale	65.07	20,000	1,301,410	247,863	Nov 14 08:45 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Option Exercise	17.00	10,000	170,000	120,994	Nov 13 04:20 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Sale	64.00	10,000	640,000	110,994	Nov 13 04:20 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Option Exercise	1.47	30,000	44,057	377,863	Nov 12 08:12 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Sale	60.31	30,000	1,809,306	347,863	Nov 12 08:12 PM
MARK A GOLDSMITH	Director	Nov 12 '25	Proposed Sale	64.08	20,000	1,281,600		Nov 12 04:40 PM
JACK LEE ANDERS	Officer	Nov 11 '25	Proposed Sale	62.73	10,000	627,300		Nov 12 07:04 AM
MARK A GOLDSMITH	Director	Nov 07 '25	Proposed Sale	61.38	30,000	1,841,400		Nov 07 04:38 PM
MARK A GOLDSMITH	Director	Oct 17 '25	Proposed Sale	49.68	10,000	496,800		Oct 17 04:18 PM
JEFFREY TODD CISLINI	Officer	Oct 17 '25	Proposed Sale	49.68	12,000	596,160		Oct 17 04:17 PM
MARK A GOLDSMITH	Director	Oct 16 '25	Proposed Sale	49.56	10,000	495,600		Oct 16 04:21 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Option Exercise	4.73	25,000	118,250	309,047	Oct 15 05:09 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Sale	48.54	25,000	1,213,540	284,047	Oct 15 05:09 PM
Cislini Jeff	General Counsel	Sep 24 '25	Sale	44.26	1,799	79,624	50,425	Sep 26 04:13 PM
JEFFREY TODD CISLINI	Officer	Sep 24 '25	Proposed Sale	44.21	1,799	79,525		Sep 24 04:21 PM
Wei Lin	Chief Medical Officer	Sep 16 '25	Sale	45.82	2,160	98,982	88,339	Sep 18 04:39 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '25	Sale	45.82	5,367	245,942	284,047	Sep 18 04:38 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '25	Sale	45.82	13,411	614,558	452,309	Sep 18 04:37 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '25	Sale	45.82	4,775	218,814	145,900	Sep 18 04:36 PM
Cislini Jeff	General Counsel	Sep 16 '25	Sale	45.82	1,869	85,647	52,224	Sep 18 04:35 PM
Anders Jack	Chief Financial Officer	Sep 16 '25	Sale	45.82	2,320	106,314	110,994	Sep 18 04:34 PM
Wei Lin	Officer	Sep 15 '25	Proposed Sale	46.55	2,131	99,198		Sep 15 09:32 PM
Kelsey Stephen Michael	Officer	Sep 15 '25	Proposed Sale	46.55	5,296	246,529		Sep 15 09:28 PM
Horn Margaret A	Officer	Sep 15 '25	Proposed Sale	46.55	4,712	219,344		Sep 15 09:24 PM
GOLDSMITH MARK A	Officer	Sep 15 '25	Proposed Sale	46.55	13,236	616,136		Sep 15 09:20 PM
Cislini Jeff	Officer	Sep 15 '25	Proposed Sale	46.55	1,842	85,745		Sep 15 09:18 PM
Anders Jack	Officer	Sep 15 '25	Proposed Sale	46.55	2,128	99,058		Sep 15 09:14 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Option Exercise	4.73	100,000	473,000	389,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Option Exercise	4.73	25,000	118,250	314,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Sale	44.08	100,000	4,408,482	289,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Sale	45.97	25,000	1,149,272	289,414	Sep 15 08:51 PM
STEPHEN M. KELSEY	Officer	Sep 11 '25	Proposed Sale	40.45	150,000	6,067,500		Sep 11 04:30 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Option Exercise	9.53	5,238	49,917	118,552	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Option Exercise	3.52	4,762	16,756	118,076	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Sale	40.17	5,238	210,432	113,314	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Sale	40.02	4,762	190,560	113,314	Sep 04 07:05 PM
JACK LEE ANDERS	Officer	Sep 02 '25	Proposed Sale	37.97	10,000	379,700		Sep 02 04:41 PM
GOLDSMITH MARK A	See Remarks	Jun 30 '25	Option Exercise	0.54	37,000	19,980	465,720	Jul 02 04:11 PM
Cislini Jeff	General Counsel	Jun 20 '25	Sale	39.61	1,912	75,736	54,093	Jun 23 04:07 PM
JEFFREY TODD CISLINI	Officer	Jun 20 '25	Proposed Sale	39.93	1,912	76,346		Jun 20 04:23 PM
Horn Margaret A	Chief Operating Officer	Jun 16 '25	Sale	39.83	3,510	139,803	150,675	Jun 18 04:06 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '25	Sale	39.83	13,496	537,546	428,720	Jun 18 04:06 PM
Cislini Jeff	General Counsel	Jun 16 '25	Sale	39.83	1,878	74,801	56,005	Jun 18 04:06 PM
Anders Jack	Chief Financial Officer	Jun 16 '25	Sale	39.83	2,170	86,431	113,314	Jun 18 04:05 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '25	Sale	39.83	4,289	170,831	289,414	Jun 18 04:05 PM
Wei Lin	Chief Medical Officer	Jun 16 '25	Sale	39.83	2,173	86,551	90,499	Jun 18 04:05 PM
Wei Lin	Officer	Jun 16 '25	Proposed Sale	40.79	2,131	86,923		Jun 13 05:25 PM
Kelsey Stephen Michael	Officer	Jun 16 '25	Proposed Sale	40.79	3,732	152,228		Jun 13 05:05 PM
Horn Margaret A	Officer	Jun 16 '25	Proposed Sale	40.79	3,320	135,423		Jun 13 05:03 PM
GOLDSMITH MARK A	Officer	Jun 16 '25	Proposed Sale	40.79	13,235	539,856		Jun 13 05:00 PM
Cislini Jeff	Officer	Jun 16 '25	Proposed Sale	40.79	1,842	75,135		Jun 13 04:58 PM
Anders Jack	Officer	Jun 16 '25	Proposed Sale	40.79	2,127	86,760		Jun 13 04:55 PM
Cislini Jeff	General Counsel	Mar 20 '25	Sale	38.71	2,041	79,008	57,723	Mar 24 04:55 PM
JEFFREY TODD CISLINI	Officer	Mar 20 '25	Proposed Sale	38.75	2,041	79,089		Mar 20 04:32 PM
Cislini Jeff	General Counsel	Mar 17 '25	Sale	39.04	1,458	56,921	59,764	Mar 19 05:43 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '25	Sale	39.04	11,738	458,255	441,564	Mar 19 05:43 PM
Anders Jack	Chief Financial Officer	Mar 17 '25	Sale	39.04	1,864	72,771	115,006	Mar 19 05:42 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '25	Sale	39.04	3,058	119,385	153,533	Mar 19 05:41 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '25	Sale	39.04	3,294	128,599	293,051	Mar 19 05:40 PM
Anders Jack	Officer	Mar 17 '25	Proposed Sale	38.89	2,108	81,980		Mar 14 05:42 PM
Cislini Jeff	Officer	Mar 17 '25	Proposed Sale	38.89	1,650	64,168		Mar 14 05:14 PM
Kelsey Stephen Michael	Officer	Mar 17 '25	Proposed Sale	38.89	3,611	140,432		Mar 14 04:47 PM
Horn Margaret A	Officer	Mar 17 '25	Proposed Sale	38.89	3,406	132,459		Mar 14 04:18 PM
GOLDSMITH MARK A	Officer	Mar 17 '25	Proposed Sale	38.89	11,890	462,402		Mar 14 04:09 PM
Cislini Jeff	General Counsel	Jan 21 '25	Sale	40.50	2,406	97,443	39,222	Jan 22 05:30 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '25	Proposed Sale	40.29	2,406	96,938		Jan 21 04:20 PM
GOLDSMITH MARK A	See Remarks	Dec 18 '24	Option Exercise	0.49	30,846	15,115	355,902	Dec 20 04:50 PM
Horn Margaret A	Chief Operating Officer	Dec 16 '24	Sale	45.40	4,329	196,553	127,991	Dec 18 04:09 PM
GOLDSMITH MARK A	See Remarks	Dec 16 '24	Sale	45.40	11,714	531,860	325,056	Dec 18 04:08 PM
Kelsey Stephen Michael	See Remarks	Dec 16 '24	Sale	45.40	4,663	211,718	259,745	Dec 18 04:07 PM
Cislini Jeff	General Counsel	Dec 16 '24	Sale	45.40	1,599	72,601	41,628	Dec 18 04:07 PM
Anders Jack	Chief Financial Officer	Dec 16 '24	Sale	45.40	2,635	119,639	96,470	Dec 18 04:06 PM
GOLDSMITH MARK A	Officer	Dec 16 '24	Proposed Sale	44.93	11,561	519,436		Dec 16 09:35 PM
Kelsey Stephen Michael	Officer	Dec 16 '24	Proposed Sale	44.93	4,604	206,858		Dec 16 08:42 PM
Cislini Jeff	Officer	Dec 16 '24	Proposed Sale	44.93	1,432	64,340		Dec 16 08:01 PM
Horn Margaret A	Officer	Dec 16 '24	Proposed Sale	44.93	4,271	191,896		Dec 16 07:39 PM
Anders Jack	Officer	Dec 16 '24	Proposed Sale	44.93	2,600	116,818		Dec 16 04:57 PM
Schroeder Thilo	Director	Dec 05 '24	Buy	46.00	1,304,347	59,999,962	2,096,612	Dec 09 04:15 PM

Open in Screener

CRWV

CoreWeave Inc

Nov 14 • 04:00PM ET

77.36

-0.98 -1.25 %

Technology • Software - Infrastructure • USA • NASD

Held by: VXF VUG VTI VO ULTY SKYY FDN VOT ARKW FBCG

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	43.18%	Shs Outstand	384.86M	Perf Week	-25.62%
Market Cap	38.13B	Forward P/E	-	EPS next Y	-0.32	Insider Trans	-15.69%	Shs Float	283.14M	Perf Month	-45.42%
Enterprise Value	54.40B	PEG	-	EPS next Q	-0.50	Inst Own	43.13%	Short Float	9.26%	Perf Quarter	-20.08%
Income	-824.73M	P/S	8.85	EPS this Y	-469.20%	Inst Trans	9.32%	Short Ratio	0.86	Perf Half Y	-3.66%
Sales	4.31B	P/B	9.93	EPS next Y	79.41%	ROA	-3.26%	Short Interest	26.21M	Perf YTD	93.40%
Book/sh	7.79	P/C	15.02	EPS next 5Y	-	ROE	-29.17%	52W High	187.00 -58.63%	Perf Year	-
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	-449.58% -	ROIC	-4.44%	52W Low	33.51 130.82%	Perf 3Y	-
Dividend Est.	0.02 (0.02%)	EV/EBITDA	25.24	Sales past 3/5Y	1000.00% -	Gross Margin	49.23%	Volatility	9.26% 7.02%	Perf 5Y	-
Dividend TTM	-	EV/Sales	12.63	EPS Y/Y TTM	19.90%	Oper. Margin	3.63%	ATR (14)	9.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.49	Sales Y/Y TTM	235.40%	Profit Margin	-19.15%	RSI (14)	23.99	Recom	2.13
Dividend Gr. 3/5Y	- -	Current Ratio	0.49	EPS Q/Q	75.23%	SMA20	-32.95%	Beta	-	Target Price	131.92
Payout	-	Debt/Eq	4.85	Sales Q/Q	133.70%	SMA50	-37.01%	Rel Volume	1.72	Prev Close	78.34
Employees	-	LT Debt/Eq	3.79	Earnings	Nov 10 AMC	SMA200	-28.67%	Avg Volume	30.41M	Price	77.36
IPO	Mar 28, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	79.53% 6.05%	Trades		Volume	52,232,600	Change	-1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-25	Downgrade	JP Morgan	Overweight → Neutral	$110
Sep-30-25	Initiated	Evercore ISI	Outperform	$175
Sep-23-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$170
Sep-23-25	Upgrade	Melius	Hold → Buy	$165
Sep-19-25	Initiated	Loop Capital	Buy	$165
Sep-16-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$180
Sep-16-25	Initiated	Raymond James	Outperform	$130
Aug-27-25	Initiated	Cantor Fitzgerald	Overweight	$116
Aug-21-25	Upgrade	H.C. Wainwright	Neutral → Buy	$180
Aug-21-25	Upgrade	Arete	Neutral → Buy	$180
Jul-31-25	Upgrade	Citigroup	Neutral → Buy	$160
Jul-17-25	Initiated	HSBC Securities	Reduce	$32
Jul-11-25	Initiated	Argus	Buy	$200
Jul-10-25	Downgrade	Needham	Buy → Hold
Jul-08-25	Downgrade	Stifel	Buy → Hold	$115
Jul-08-25	Downgrade	Mizuho	Outperform → Neutral	$150
Jun-25-25	Initiated	H.C. Wainwright	Neutral
Jun-16-25	Downgrade	BofA Securities	Buy → Neutral	$185
Jun-05-25	Initiated	Arete	Neutral	$130
May-27-25	Downgrade	Barclays	Overweight → Equal Weight	$100

Show Previous Ratings

Today 07:03AM	As government reopens, AI stocks crack as supply problems emerge (Detroit Free Press)
07:00AM	MarketBeat Week in Review - 11/10 - 11/14 (MarketBeat)
Nov-14-25 07:47PM	Leaked documents shed light into how much OpenAI pays Microsoft (TechCrunch)
06:05PM	AI Debt Megadeals: A Lot of Risk, a Lot of Uncertainty (Barrons.com)
04:28PM	Why CoreWeave Stock Collapsed 25.4% This Week (Motley Fool)
04:01PM	Loading…
04:01PM	Philippe Laffont's Strategic Moves: CoreWeave Inc Faces a -5.03% Portfolio Impact (GuruFocus.com)
03:46PM	'Buy the Dip' Is Still Alive. The AI Trade Is Too. (Barrons.com)
12:57PM	AI Stocks Hit Turbulence: Will Electrical Grid Issues Short-Circuit AI Revolution? (Investor's Business Daily)
12:55PM	Stock Market Rises Amid Wild Swings As Government Shutdown Ends: Weekly Review (Investor's Business Daily)
12:18PM	How Long Will Traders Keep Buying the Dip in AI? (The Wall Street Journal)
11:14AM	AI and Quantum Players See Steep Pullback as Market Demands Revenue Clarity (GuruFocus.com)
10:53AM	2 Future AI IPOs I Couldnt Be More Excited About (24/7 Wall St.)
10:32AM	Nvidia Reports Earnings Next Week. How Big of a Blowout Will It Be? (24/7 Wall St.)
10:16AM	Nvidia Stock Wavers With Earnings Due As AI Sell-Off Intensifies (Investor's Business Daily)
10:00AM	Quarterly Earnings News - How AI is Shaping Record Growth across Multiple Sectors (Newsfile)
09:49AM	Loading…
09:49AM	AI Anxiety Reaches Fever Pitch in the Stock Market. Why It's Still Not Time to Worry. (Barrons.com)
09:22AM	THE MINING POD: Bitcoin Mining Stock Prices Lose $20B, Bitdeers Data Center Fire, Auradines New Unit, Jim Cramer Yells at CRWV (CoinDesk)
08:53AM	Earnings live: Applied Materials stock falls, Trump brothers' American Bitcoin revenue doubles (Yahoo Finance)
08:40AM	Nebius Shares Fall Post Q3 Earnings: Should Investors Hold or Sell? (Zacks)
07:48AM	This Little-Known AI Stock Is Up 311% in 2025, and History Says It Could Soar Again in 2026 (Hint: Not Palantir) (Motley Fool)
07:37AM	Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia (Zacks)
07:26AM	Can Nebius Reach its 2026 ARR Target Amid Soaring AI Demand? (Zacks)
04:06AM	CoreWeave Stock Has Lost More Than a Third of Its Value in 3 Months. Time to Buy? (Motley Fool)
03:00AM	Bitcoin Mining Stock Prices Lose $20B, Bitdeers Data Center Fire, Auradines New Unit, Jim Cramer Yells at CRWV (Blockspace)
Nov-13-25 04:21PM	Earnings live: Applied Materials stock falls, Disney tumbles, Cisco rises (Yahoo Finance) -8.30%
04:19PM	These Stocks Moved the Most Today: Disney, Cisco, Tesla, CoreWeave, Micron, Circle, Nike, and More (Barrons.com)
04:10PM	CoreWeave Stock Dives 8% Amid Tech Selloff (The Wall Street Journal)
03:44PM	CoreWeave Stock Drops Again-and the Bond Market Is Starting to Worry, Too (Barrons.com)
03:41PM	AI Anxiety Reaches Fever Pitch. Why It's Still Not Time to Worry. (Barrons.com)
03:22PM	These Stocks Are Moving the Most Today: Disney, Cisco, Tesla, CoreWeave, Micron, Circle, Nike, and More (Barrons.com)
02:49PM	Loading…
02:49PM	CoreWeave Has Boots on the Ground to Solve Data Center Delays. Should You Bet on a Rebound in CRWV Stock? (Barchart)
01:09PM	CoreWeave Stock Drops Again. Insuring Against an AI Slowdown Is Getting Expensive. (Barrons.com)
12:47PM	Can Equities Stabilize after the Government Reopens? (Zacks)
12:31PM	Tesla Stock Drops. Retail Investors Keep Buying. (Barrons.com)
12:09PM	Jim Cramer on CoreWeave: "The Missed Quarter Shocked People" (Insider Monkey)
11:45AM	Will CoreWeave's Heavy Debt Load Disrupt Its Growth Momentum? (Zacks)
10:52AM	CoreWeave stock falls after The Verge labels it "heart of AI bubble" (Investing.com)
10:45AM	Down 35%, Is CoreWeave a Buy on the Dip? (Motley Fool)
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
09:16AM	Can CoreWeave Sustain its Edge Amid Surging AI Cloud Demand? (Zacks)
09:10AM	Here Are Thursdays Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More (24/7 Wall St.)
09:05AM	CoreWeave Announces Zero Egress Migration, Unlocking Multi-Cloud Development for AI Workloads (Business Wire)
08:15AM	2 Core AI Infrastructure Stocks I'd Buy Now (Motley Fool)
07:32AM	Oracle Stock Keeps Getting Crushed. It Can Soar 75%, Analyst Says. (Barrons.com)
07:19AM	Earnings live: Disney stock falls as revenue misses, Cisco surges, chipmaker SMIC rises (Yahoo Finance)
Nov-12-25 06:38PM	Oracle and CoreWeave represent 'bad behavior' in the AI buildout, says DA Davidson's Gil Luria (CNBC TV)
04:51PM	Earnings live: Cisco stock pops, Circle slides, On Holding and McGraw Hill stocks surge (Yahoo Finance)
01:33PM	CoreWeave CEO fires back as investors lose patience (TheStreet)
12:32PM	CoreWeave Has a Tremendous Long-Term Opportunity But Is Stuck in Limbo Here. Should You Buy, Sell, or Hold CRWV Stock for 2026? (Barchart)
12:14PM	This Growth Stock Is Down 35%. Buy or Wait? (Motley Fool)
12:12PM	Why Are Nebius, CoreWeave, and Iren Stock Falling? (Motley Fool)
12:09PM	Jim Cramer Discusses CoreWeave (CRWV)'s Debt Levels (Insider Monkey)
11:21AM	Anthropic announces $50B investment in new US data centers to meet AI demand (Associated Press Finance)
11:20AM	Nebius Stock Falls, CoreWeave Steadies After AI Selloff. Why Another Shoe Could Drop. (Barrons.com)
11:17AM	CoreWeave Slides Post Q3 Earnings: Is It Time to Buy the Stock? (Zacks)
11:16AM	Oracle Stock Keeps Getting Crushed. It Can Soar 70%, Analyst Says. (Barrons.com)
09:35AM	DraftKings downgraded, Instacart upgraded: Wall Streets top analyst calls (TipRanks)
09:00AM	CoreWeave Expands Revolving Credit Facility to $2.5 Billion to Support Growth (Business Wire)
08:26AM	Nebius Stock, CoreWeave Steady After AI Selloff. Why Another Shoe Could Drop. (Barrons.com)
08:20AM	Earnings live: Circle stock slides as the stablecoin issuer's revenue jumps, On Holding stock surges (Yahoo Finance)
08:20AM	Earnings live: Circle stock slides as the stablecoin issuer's Q3 revenue jumps, On Holding stock surges (Yahoo Finance)
08:16AM	Earnings live: Circle stock slides, On Holding stock jumps on holiday quarter forecast (Yahoo Finance)
08:12AM	CoreWeave, Nebius, IREN Stocks Steady After AI Bubble Fears. They're Still High Risk. (Barrons.com)
07:39AM	CoreWeave: Explosive AI Cloud Growth, But Supply Chains Pose A Risk (GuruFocus.com)
05:47AM	Microsoft commits $10bn to AI data centre park in Portugal (Verdict)
05:30AM	The AI Boom Is Looking More and More Fragile (The Wall Street Journal)
04:44AM	Should You Buy CoreWeave Stock on the Dip? (Motley Fool)
04:10AM	Billionaire Philippe Laffont Sells Super Micro Stock and Buys an AI Stock That Could Soar 100% (Motley Fool)
03:31AM	Heard on the Street Tuesday Recap: Getting to Yes (The Wall Street Journal)
Nov-11-25 07:11PM	CoreWeave's Guidance Cut: A Buying Opportunity in Disguise? (MarketBeat) -16.31%
05:47PM	Bank of America resets price target as CoreWeave earnings send stock reeling (TheStreet)
04:49PM	Dow Jones Hits Record Close With Palantir, Eli Lilly In Buy Areas; These AI Stocks Tumble (Investor's Business Daily)
04:49PM	CoreWeave Earnings Beat Estimates. Why the Stock Dropped 16% Today. (Barrons.com)
04:45PM	Government Shutdown Nears End, Lifting Investors Spiritsand Stocks (The Wall Street Journal)
04:26PM	Stocks to Watch Tuesday Recap: Paramount, CoreWeave, Beyond Meat (The Wall Street Journal)
04:23PM	These Stocks Moved the Most Today: CoreWeave, Nvidia, Tesla, Nebius, Rigetti, BigBear.ai, Rocket Lab, and More (Barrons.com)
04:21PM	Stock Market Today: Dow Surges As Shutdown End Nears; Buffett Stock Gets Hot (Live Coverage) (Investor's Business Daily)
04:15PM	CoreWeave Drops After Lowering Outlook on Capacity Crunch (Bloomberg)
04:10PM	CoreWeave to Participate in the Wells Fargo TMT Conference (Business Wire)
04:00PM	Stock market today: Dow jumps over 500 points to record close, Nvidia's slide drags on Nasdaq (Yahoo Finance)
04:00PM	Stock market today: Dow jumps 500 points to record close, Nvidia's slide drags on Nasdaq (Yahoo Finance)
02:45PM	Why CoreWeave Stock Is Plummeting Today (Motley Fool)
02:27PM	Oracle share price weakness offers a buying opportunity, says Mizuho (Investing.com)
02:24PM	CoreWeave Bends the Law of Large Numbers: Heard on the Street (The Wall Street Journal)
02:19PM	Stock Market Today: Dow Jumps 500 Points As Shutdown End Nears; Buffett Stock Gets Hot (Live Coverage) (Investor's Business Daily)
02:16PM	Airline stocks slip on continued delays, Beyond Meat stock falls (Yahoo Finance Video)
02:16PM	These Stocks Are Moving the Most Today: CoreWeave, Nvidia, Tesla, Nebius, Rigetti, BigBear.ai, Rocket Lab, and More (Barrons.com)
01:34PM	CoreWeave CEO on AI infrastructure: Delay will 'clear itself shortly' (CNBC TV)
12:43PM	Michael Burry's Latest Warning Could Be Bad News for CoreWeave (Motley Fool)
12:34PM	Jefferies' Brent Thill: CoreWeave setback 'shows you the danger of the AI trade' (CNBC TV)
12:33PM	Stock Market Today: Indexes Mixed As Shutdown End Looms; Nvidia Slides On OpenAI News (Live Coverage) (Investor's Business Daily)
12:25PM	Tech, Media & Telecom Roundup: Market Talk (The Wall Street Journal)
12:05PM	CoreWeave receives downgrade, The RealReal hits 52-week high (Yahoo Finance Video)
11:56AM	CoreWeave CEO Addresses Data-Center Delay, Supply Chain and Nvidia (Bloomberg)
11:52AM	CoreWeave Working to Diversify Suppliers, Says CEO Intrator (Bloomberg)
11:34AM	CoreWeave slides after earnings: Here's what to know (CNBC TV)
11:34AM	CoreWeave CEO responds to data center delay as stock falls (CNBC TV)
11:28AM	3 Things We Learned from CoreWeaves Blowout Q3 Earnings (24/7 Wall St.)
11:10AM	Top Analysts See S&P 500 Climbing 7,500 by 2026 on AI Momentum (GuruFocus.com)
10:59AM	Nebiuss 355% Revenue Hike Misses Forecasts. This AI Deal Isnt Enough to Lift the Stock. (Barrons.com)

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venturo Brian M	Chief Strategy Officer	Nov 12 '25	Sale	87.57	281,250	24,630,107	0	Nov 14 08:37 PM
Goldberg Chen	SVP of Engineering	Nov 11 '25	Sale	90.79	13,740	1,247,468	23,344	Nov 13 04:31 PM
HUTCHINS GLENN H	Director	Nov 10 '25	Option Exercise	0.00	1,940	0	5,860	Nov 13 04:27 PM
WEST CLAY CAPITAL LLC	Director	Nov 12 '25	Proposed Sale	88.39	281,250	24,859,688		Nov 12 04:39 PM
CHEN GOLDBERG	Officer	Nov 11 '25	Proposed Sale	105.61	13,740	1,451,081		Nov 12 07:06 AM
Goldberg Chen	SVP of Engineering	Nov 05 '25	Option Exercise	0.00	37,500	0	56,264	Nov 07 07:02 PM
Goldberg Chen	SVP of Engineering	Nov 05 '25	Sale	118.30	19,180	2,268,994	37,084	Nov 07 07:02 PM
Intrator Michael N	CEO and President	Nov 05 '25	Sale	113.97	50,000	5,698,584	0	Nov 07 07:00 PM
Intrator Michael N	CEO and President	Nov 05 '25	Sale	113.97	32,455	3,698,950	6,991,055	Nov 07 07:00 PM
Magnetar Financial LLC	10% Owner	Nov 03 '25	Sale	134.94	7,688	1,037,382	299,512	Nov 05 09:02 PM
Venturo Brian M	Chief Strategy Officer	Nov 03 '25	Sale	127.94	29,916	3,827,363	215,486	Nov 05 07:34 PM
Chen Goldberg	Officer	Nov 05 '25	Proposed Sale	118.30	19,180	2,268,994		Nov 05 06:30 PM
MICHAEL INTRATOR	Director	Nov 05 '25	Proposed Sale	115.75	32,455	3,756,666		Nov 05 04:21 PM
OMNADORA CAPITAL LLC	Director	Nov 05 '25	Proposed Sale	115.75	50,000	5,787,500		Nov 05 04:20 PM
YOLO APV TRUST	Director	Nov 03 '25	Proposed Sale	133.71	14,958	2,000,034		Nov 03 04:27 PM
YOLO ECV TRUST	Director	Nov 03 '25	Proposed Sale	133.71	14,958	2,000,034		Nov 03 04:27 PM
Magnetar Financial LLC	10% Owner	Oct 31 '25	Sale	135.65	191,331	25,953,371	853,869	Oct 31 09:38 PM
Magnetar Financial LLC	10% Owner	Oct 31 '25	Sale	135.65	331,324	44,942,837	299,543	Oct 31 09:36 PM
Magnetar Financial LLC	10% Owner	Oct 30 '25	Sale	134.69	216,010	29,094,650	301,490	Oct 31 09:34 PM
Venturo Brian M	Chief Strategy Officer	Oct 29 '25	Sale	137.80	281,250	38,755,380	0	Oct 31 05:30 PM
Magnetar Financial LLC	10% Owner	Oct 29 '25	Sale	138.48	464,169	64,279,131	862,889	Oct 29 09:40 PM
Magnetar Financial LLC	10% Owner	Oct 29 '25	Sale	138.48	804,514	111,412,046	302,294	Oct 29 09:39 PM
Magnetar Financial LLC	10% Owner	Oct 28 '25	Sale	138.61	378,293	52,436,174	878,399	Oct 29 09:31 PM
Magnetar Financial LLC	10% Owner	Oct 28 '25	Sale	138.61	435,637	60,384,774	307,007	Oct 29 09:30 PM
Magnetar Financial LLC	10% Owner	Oct 28 '25	Sale	138.61	639,675	88,666,857	1,633,981	Oct 29 09:29 PM
Magnetar Financial LLC	10% Owner	Oct 27 '25	Sale	135.02	531,599	71,776,505	312,427	Oct 29 09:28 PM
Jeffrey R Baker	Officer	Oct 29 '25	Proposed Sale	134.80	6,398	862,450		Oct 29 09:25 PM
WEST CLAY CAPITAL LLC	Director	Oct 29 '25	Proposed Sale	134.80	281,250	37,912,500		Oct 29 04:25 PM
Intrator Michael N	CEO and President	Oct 22 '25	Sale	118.57	50,000	5,928,690	0	Oct 24 05:45 PM
Intrator Michael N	CEO and President	Oct 22 '25	Sale	118.58	32,455	3,848,450	7,023,510	Oct 24 05:45 PM
Magnetar Financial LLC	10% Owner	Oct 20 '25	Sale	136.73	44,181	6,040,836	314,405	Oct 22 08:17 PM
MICHAEL INTRATOR	Director	Oct 22 '25	Proposed Sale	125.06	32,455	4,058,822		Oct 22 04:36 PM
OMNADORA CAPITAL LLC	Director	Oct 22 '25	Proposed Sale	125.06	50,000	6,253,000		Oct 22 04:18 PM
Magnetar Financial LLC	10% Owner	Oct 17 '25	Sale	136.62	18,371	2,509,857	903,175	Oct 17 08:46 PM
Magnetar Financial LLC	10% Owner	Oct 17 '25	Sale	136.62	244,203	33,361,925	314,572	Oct 17 08:45 PM
Magnetar Financial LLC	10% Owner	Oct 16 '25	Sale	143.51	303,206	43,513,560	906,354	Oct 17 08:20 PM
Magnetar Financial LLC	10% Owner	Oct 16 '25	Sale	143.51	549,087	78,800,232	1,309,675	Oct 17 08:20 PM
Magnetar Financial LLC	10% Owner	Oct 16 '25	Sale	143.51	254,525	36,527,255	315,541	Oct 17 08:19 PM
Magnetar Financial LLC	10% Owner	Oct 16 '25	Sale	143.51	1,004,073	144,096,539	2,246,787	Oct 17 08:18 PM
Magnetar Financial LLC	10% Owner	Oct 15 '25	Sale	138.75	12,876	1,786,505	932,272	Oct 17 08:17 PM
Magnetar Financial LLC	10% Owner	Oct 15 '25	Sale	138.75	495,122	68,696,626	1,375,868	Oct 17 08:16 PM
Magnetar Financial LLC	10% Owner	Oct 15 '25	Sale	138.76	556,230	77,184,305	323,465	Oct 17 08:15 PM
Venturo Brian M	Chief Strategy Officer	Oct 15 '25	Sale	138.47	154,479	21,390,060	0	Oct 17 05:41 PM
Magnetar Financial LLC	10% Owner	Oct 14 '25	Sale	137.19	17,789	2,440,449	327,394	Oct 15 08:02 PM
Magnetar Financial LLC	10% Owner	Oct 13 '25	Sale	141.27	27,945	3,947,818	945,366	Oct 15 08:01 PM
Magnetar Financial LLC	10% Owner	Oct 13 '25	Sale	141.27	369,379	52,183,136	327,460	Oct 15 08:00 PM
WEST CLAY CAPITAL LLC	Director	Oct 15 '25	Proposed Sale	134.06	154,479	20,709,455		Oct 15 04:28 PM
Magnetar Financial LLC	10% Owner	Oct 10 '25	Sale	148.74	414,547	61,658,723	1,845,583	Oct 14 06:00 AM
Magnetar Financial LLC	10% Owner	Oct 10 '25	Sale	148.80	180,166	26,807,874	328,932	Oct 10 09:59 PM
Magnetar Financial LLC	10% Owner	Oct 10 '25	Sale	148.80	208,207	30,980,194	950,211	Oct 10 09:59 PM
Magnetar Financial LLC	10% Owner	Oct 09 '25	Sale	141.16	372,706	52,611,485	959,976	Oct 10 09:52 PM
Magnetar Financial LLC	10% Owner	Oct 09 '25	Sale	141.16	907,277	128,070,413	331,908	Oct 10 09:51 PM
Magnetar Financial LLC	10% Owner	Oct 08 '25	Sale	139.46	691,243	96,403,190	336,663	Oct 10 08:13 PM
Intrator Michael N	CEO and President	Oct 08 '25	Sale	139.66	15,174	2,119,125	0	Oct 09 05:33 PM
Intrator Michael N	CEO and President	Oct 07 '25	Sale	131.54	61,810	8,130,424	7,088,420	Oct 09 05:32 PM
Intrator Michael N	CEO and President	Oct 08 '25	Sale	135.44	34,826	4,716,971	15,174	Oct 09 05:32 PM
Intrator Michael N	CEO and President	Oct 08 '25	Sale	136.72	32,455	4,437,309	7,055,965	Oct 09 05:32 PM
Venturo Brian M	Chief Strategy Officer	Oct 06 '25	Sale	137.90	52,787	7,279,090	248,722	Oct 08 04:52 PM
Boone Karen	Director	Oct 06 '25	Option Exercise	0.00	1,720	0	5,160	Oct 08 04:50 PM
OMNADORA CAPITAL LLC	Director	Oct 08 '25	Proposed Sale	128.83	50,000	6,441,500		Oct 08 04:20 PM
MICHAEL INTRATOR	Director	Oct 08 '25	Proposed Sale	128.83	32,455	4,181,178		Oct 08 04:19 PM
Magnetar Financial LLC	10% Owner	Oct 07 '25	Sale	137.63	63,318	8,714,374	339,232	Oct 07 09:07 PM
Magnetar Financial LLC	10% Owner	Oct 06 '25	Sale	139.27	570,463	79,447,333	339,469	Oct 07 08:11 PM
Magnetar Financial LLC	10% Owner	Oct 03 '25	Sale	139.37	1,149,406	160,196,853	341,592	Oct 07 08:09 PM
MICHAEL INTRATOR	Director	Oct 07 '25	Proposed Sale	133.85	61,810	8,273,268		Oct 07 04:21 PM
BRIAN VENTURO	Director	Oct 06 '25	Proposed Sale	134.79	52,787	7,115,160		Oct 06 04:19 PM
Venturo Brian M	Chief Strategy Officer	Oct 01 '25	Sale	135.67	310,480	42,122,663	0	Oct 03 06:15 PM
Magnetar Financial LLC	10% Owner	Oct 02 '25	Sale	138.20	149,524	20,664,788	1,005,811	Oct 02 09:24 PM
Magnetar Financial LLC	10% Owner	Oct 02 '25	Sale	138.22	901,524	124,605,999	345,860	Oct 02 09:23 PM
Magnetar Financial LLC	10% Owner	Oct 01 '25	Sale	137.11	286,323	39,257,747	349,760	Oct 02 08:20 PM
Magnetar Financial LLC	10% Owner	Sep 30 '25	Sale	139.55	99,691	13,911,778	1,022,058	Oct 02 08:17 PM
Magnetar Financial LLC	10% Owner	Sep 30 '25	Sale	139.55	581,484	81,145,574	1,605,140	Oct 02 08:15 PM
Magnetar Financial LLC	10% Owner	Sep 30 '25	Sale	139.55	732,944	102,280,892	350,819	Oct 02 08:14 PM
Venturo Brian M	Chief Strategy Officer	Sep 30 '25	Option Exercise	0.00	126,771	0	367,102	Oct 02 06:49 PM
Venturo Brian M	Chief Strategy Officer	Sep 30 '25	Sale	139.44	65,593	9,146,288	301,509	Oct 02 06:49 PM
McBee Brannin	Chief Development Officer	Sep 30 '25	Option Exercise	0.00	121,119	0	243,084	Oct 02 06:47 PM
McBee Brannin	Chief Development Officer	Sep 30 '25	Sale	138.59	157,903	21,884,290	185,181	Oct 02 06:47 PM
McBee Brannin	Chief Development Officer	Sep 30 '25	Sale	138.10	150,000	20,715,440	0	Oct 02 06:47 PM
Intrator Michael N	CEO and President	Sep 30 '25	Option Exercise	0.00	140,358	0	7,228,778	Oct 02 06:43 PM
Intrator Michael N	CEO and President	Sep 30 '25	Sale	139.44	78,548	10,952,733	7,150,230	Oct 02 06:43 PM
WEST CLAY CAPITAL LLC	Director	Oct 01 '25	Proposed Sale	136.85	281,250	38,489,062		Oct 01 04:35 PM
YOLO APV TRUST	Director	Oct 01 '25	Proposed Sale	136.85	14,615	2,000,063		Oct 01 04:34 PM
YOLO ECV TRUST	Director	Oct 01 '25	Proposed Sale	136.85	14,615	2,000,063		Oct 01 04:34 PM
Brian Venturo	Officer	Sep 30 '25	Proposed Sale	139.44	65,593	9,146,288		Sep 30 08:49 PM
Michael N Intrator	Officer	Sep 30 '25	Proposed Sale	139.44	78,548	10,952,733		Sep 30 08:27 PM
BRANNIN J. MCBEE 2022 IRR TRUS	Officer	Sep 30 '25	Proposed Sale	122.52	150,000	18,378,000		Sep 30 04:28 PM
BRANNIN MCBEE	Officer	Sep 30 '25	Proposed Sale	122.52	157,903	19,346,276		Sep 30 04:28 PM
Intrator Michael N	CEO and President	Sep 24 '25	Sale	130.14	50,000	6,506,980	0	Sep 26 09:36 PM
Intrator Michael N	CEO and President	Sep 24 '25	Sale	130.14	32,455	4,223,680	7,088,420	Sep 26 09:36 PM
Magnetar Financial LLC	10% Owner	Sep 25 '25	Sale	136.38	185,627	25,315,999	1,039,327	Sep 26 08:08 PM
Magnetar Financial LLC	10% Owner	Sep 25 '25	Sale	136.38	1,113,847	151,907,029	356,070	Sep 26 08:06 PM
McBee Brannin	Chief Development Officer	Sep 23 '25	Sale	131.83	375,000	49,435,525	0	Sep 25 04:23 PM
McBee Brannin	Chief Development Officer	Sep 23 '25	Sale	131.83	250,000	32,957,016	121,965	Sep 25 04:23 PM
McVeety Kristen J	GC and Secretary	Sep 22 '25	Sale	126.86	95,000	12,051,675	0	Sep 24 05:03 PM
OMNADORA CAPITAL LLC	Director	Sep 24 '25	Proposed Sale	130.89	50,000	6,544,500		Sep 24 04:22 PM
MICHAEL INTRATOR	Director	Sep 24 '25	Proposed Sale	130.89	32,455	4,248,035		Sep 24 04:21 PM
BRANNIN MCBEE	Officer	Sep 23 '25	Proposed Sale	133.23	250,000	33,307,500		Sep 23 04:22 PM
BRANNIN J. MCBEE 2022 IRR TRUS	Officer	Sep 23 '25	Proposed Sale	133.23	375,000	49,961,250		Sep 23 04:22 PM
Magnetar Financial LLC	10% Owner	Sep 22 '25	Sale	132.42	734,110	97,213,538	360,900	Sep 22 09:18 PM
Magnetar Financial LLC	10% Owner	Sep 19 '25	Sale	125.60	197,336	24,784,570	1,064,159	Sep 22 08:21 PM

Open in Screener

APGE

Apogee Therapeutics Inc

Nov 14 • 04:00PM ET

65.50

+2.53 4.02 %

Healthcare • Biotechnology • USA • NASD

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BMRN SRPT IONS ALNY QURE CRSP NTLA SGMO

| Held by: XBI IWM VTI IBB IWO VXF SCHA VTWO LABU ITOT

Index	RUT	P/E	-	EPS (ttm)	-4.32	Insider Own	32.16%	Shs Outstand	59.32M	Perf Week	19.72%
Market Cap	4.47B	Forward P/E	-	EPS next Y	-4.73	Insider Trans	-0.26%	Shs Float	40.43M	Perf Month	22.66%
Enterprise Value	3.96B	PEG	-	EPS next Q	-1.00	Inst Own	85.57%	Short Float	19.67%	Perf Quarter	77.51%
Income	-253.67M	P/S	-	EPS this Y	-25.48%	Inst Trans	-2.30%	Short Ratio	11.61	Perf Half Y	61.25%
Sales	0.00M	P/B	8.13	EPS next Y	-14.15%	ROA	-36.18%	Short Interest	7.95M	Perf YTD	44.59%
Book/sh	8.05	P/C	8.49	EPS next 5Y	-19.67%	ROE	-38.41%	52W High	64.87 0.97%	Perf Year	14.21%
Cash/sh	7.72	P/FCF	-	EPS past 3/5Y	-105.02% -	ROIC	-42.84%	52W Low	26.20 150.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.54% 5.80%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-58.35%	Oper. Margin	-	ATR (14)	3.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	76.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.86	EPS Q/Q	-28.18%	SMA20	15.01%	Beta	1.43	Target Price	91.36
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	36.13%	Rel Volume	1.49	Prev Close	62.97
Employees	196	LT Debt/Eq	0.01	Earnings	Nov 10 BMO	SMA200	62.06%	Avg Volume	685.28K	Price	65.50
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.47% -	Trades		Volume	1,020,239	Change	4.02%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
09:55PM	Loading…
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
07:30AM	Loading…
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
09:55AM	Loading…
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM
Dambkowski Carl	Chief Medical Officer	May 07 '25	Sale	35.75	2,725	97,419	244,448	May 09 08:01 PM
Dambkowski Carl	Chief Medical Officer	Apr 02 '25	Sale	36.22	3,860	139,801	247,173	Apr 04 08:01 PM
CARL DAMBKOWSKI	Officer	Apr 02 '25	Proposed Sale	35.61	9,310	331,529		Apr 02 04:23 PM
Dambkowski Carl	Chief Medical Officer	Mar 05 '25	Sale	30.48	1,590	48,463	251,033	Mar 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 05 '25	Sale	30.15	10,000	301,511	1,292,987	Mar 07 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Mar 05 '25	Proposed Sale	30.15	10,000	301,501		Mar 05 01:46 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Option Exercise	22.86	795	18,174	256,143	Feb 07 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 05 '25	Sale	40.69	3,520	143,229	252,623	Feb 07 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 05 '25	Sale	40.58	15,000	608,700	1,302,987	Feb 07 08:01 PM
HENDERSON MICHAEL THOMAS	Director	Feb 05 '25	Proposed Sale	40.58	15,000	608,728		Feb 05 02:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 31 '25	Option Exercise	22.86	8,500	194,310	1,317,987	Jan 31 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 08 '25	Sale	48.85	15,000	732,693	1,309,487	Jan 10 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Jan 08 '25	Proposed Sale	48.84	15,000	732,675		Jan 08 12:23 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Option Exercise	22.86	1,360	31,090	259,433	Jan 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 02 '25	Sale	46.94	4,085	191,740	255,348	Jan 03 08:00 PM
McKenna Mark C.	Director	Dec 12 '24	Buy	49.54	20,000	990,775	20,000	Dec 16 06:00 AM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Option Exercise	22.86	1,815	41,491	262,613	Dec 13 08:01 PM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Sale	48.76	4,540	221,363	258,073	Dec 13 08:01 PM
CARL DAMBKOWSKI	Officer	Dec 11 '24	Proposed Sale	48.38	18,160	878,581		Dec 11 04:59 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '24	Sale	46.07	6,665	307,057	260,798	Dec 06 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '24	Sale	46.58	15,000	698,654	1,324,487	Dec 06 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Dec 04 '24	Proposed Sale	46.58	15,000	698,709		Dec 04 11:12 AM

Open in Screener

KURA

Kura Oncology Inc

Nov 14 • 04:00PM ET

11.20

+0.52 4.92 %

Healthcare • Biotechnology • USA • NASD

KURA Kura Oncology Inc daily Stock Chart

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI FGEN

| Held by: VTI IWM XBI AVUV VXF IWN IBB SCHA VTWO DFAS

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	3.51%	Shs Outstand	87.02M	Perf Week	13.64%
Market Cap	975.03M	Forward P/E	-	EPS next Y	-2.25	Insider Trans	-0.84%	Shs Float	83.96M	Perf Month	10.61%
Enterprise Value	444.84M	PEG	-	EPS next Q	-0.22	Inst Own	96.57%	Short Float	10.33%	Perf Quarter	49.80%
Income	-216.88M	P/S	9.37	EPS this Y	-23.21%	Inst Trans	3.04%	Short Ratio	4.42	Perf Half Y	86.13%
Sales	104.03M	P/B	4.02	EPS next Y	9.73%	ROA	-38.45%	Short Interest	8.68M	Perf YTD	28.65%
Book/sh	2.79	P/C	1.77	EPS next 5Y	-1.76%	ROE	-65.10%	52W High	17.94 -37.54%	Perf Year	-39.66%
Cash/sh	6.32	P/FCF	11.73	EPS past 3/5Y	-0.89% -6.05%	ROIC	-84.64%	52W Low	5.41 107.12%	Perf 3Y	-17.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.20%	Volatility	11.79% 8.79%	Perf 5Y	-70.33%
Dividend TTM	-	EV/Sales	4.28	EPS Y/Y TTM	-5.18%	Oper. Margin	-230.53%	ATR (14)	0.88	Perf 10Y	38.85%
Dividend Ex-Date	-	Quick Ratio	5.12	Sales Y/Y TTM	-	Profit Margin	-208.48%	RSI (14)	64.67	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.12	EPS Q/Q	-35.14%	SMA20	10.16%	Beta	0.22	Target Price	31.45
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	18.40%	Rel Volume	2.28	Prev Close	10.68
Employees	192	LT Debt/Eq	0.06	Earnings	Nov 04 BMO	SMA200	50.81%	Avg Volume	1.96M	Price	11.20
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.44% 9.57%	Trades		Volume	4,477,504	Change	4.92%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight

Show Previous Ratings

Nov-14-25 07:15AM	Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy (Pharmaceutical Technology)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 10:51AM	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-12-25 04:05PM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:03PM	Loading…
Nov-04-25 04:03PM	Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 04:02PM	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin (GlobeNewswire)
09:14AM	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting (GlobeNewswire)
07:50AM	What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 04:01PM	Kura Oncology to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-24-25 07:02AM	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin (GlobeNewswire) +6.59%
Oct-18-25 03:23AM	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
07:30AM	Loading…
Oct-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:01AM	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-29-25 04:01PM	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-25-25 05:18PM	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology (GlobeNewswire) +8.25%
Sep-24-25 07:30AM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-16-25 04:01PM	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types (GlobeNewswire)
Sep-08-25 12:30AM	LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA) (Insider Monkey)
Sep-05-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 08:02AM	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program (GlobeNewswire) +6.04%
Aug-28-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Mar-26-25 07:30AM	Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 11:19AM	Q4 2024 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth (GuruFocus.com)
Feb-26-25 05:35PM	Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 04:01PM	Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire)
Jan-06-25 04:30PM	Kura Oncology Announces Senior Executive Promotions (GlobeNewswire)
Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:00AM	Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors (Business Wire)
Oct-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Oct-23-24 07:30AM	Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors (GlobeNewswire)
Oct-09-24 05:54PM	Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 06:30PM	Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology (GlobeNewswire)
Sep-17-24 07:30AM	Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors (GlobeNewswire)
Sep-10-24 07:30AM	Kura Oncology to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 12:01AM	Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-08-24 04:44PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Aug-01-24 07:30AM	Kura Oncology to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes (GlobeNewswire)
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bair Teresa Brophy	Chief Legal Officer	Nov 14 '25	Sale	11.18	8,804	98,401	188,139	Nov 14 08:00 PM
Powl Brian T.	Chief Commercial Officer	Nov 14 '25	Sale	11.18	8,887	99,329	139,689	Nov 14 08:00 PM
Leoni Mollie	Chief Medical Officer	Nov 14 '25	Sale	11.18	15,485	173,074	225,454	Nov 14 08:00 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Nov 14 '25	Sale	11.18	4,539	50,732	130,257	Nov 14 08:00 PM
FORD KATHLEEN	Officer	Nov 14 '25	Proposed Sale	10.68	6,902	73,713		Nov 14 08:00 PM
DOYLE THOMAS JAMES	Officer	Nov 14 '25	Proposed Sale	10.68	4,539	48,477		Nov 14 08:00 PM
FORD KATHLEEN	Chief Operating Officer	Nov 14 '25	Sale	11.18	6,902	77,143	105,373	Nov 14 08:00 PM
LEONI MOLLIE	Officer	Nov 14 '25	Proposed Sale	10.68	15,485	165,380		Nov 14 08:00 PM
POWL BRIAN T	Officer	Nov 14 '25	Proposed Sale	10.68	8,887	94,913		Nov 14 08:00 PM
BAIR TERESA BROPHY	Officer	Nov 14 '25	Proposed Sale	10.68	8,804	94,027		Nov 14 08:00 PM
WILSON TROY EDWARD	Officer	Sep 29 '25	Proposed Sale	9.05	36,615	331,366		Sep 29 07:50 PM
LEONI MOLLIE	Officer	Sep 29 '25	Proposed Sale	9.05	12,314	111,442		Sep 29 07:50 PM
POWL BRIAN T	Officer	Sep 29 '25	Proposed Sale	9.05	8,891	80,464		Sep 29 07:50 PM
BAIR TERESA BROPHY	Officer	Sep 29 '25	Proposed Sale	9.05	8,805	79,685		Sep 29 07:50 PM
DOYLE THOMAS JAMES	Officer	Sep 29 '25	Proposed Sale	9.05	4,541	41,096		Sep 29 07:50 PM
FORD KATHLEEN	Officer	Sep 29 '25	Proposed Sale	9.05	6,892	62,373		Sep 29 07:50 PM
Powl Brian T.	Chief Commercial Officer	Sep 29 '25	Sale	8.94	8,891	79,505	99,676	Sep 29 07:30 PM
Bair Teresa Brophy	Chief Legal Officer	Sep 29 '25	Sale	8.94	8,805	78,736	148,043	Sep 29 07:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 29 '25	Sale	8.94	6,892	61,630	63,375	Sep 29 07:30 PM
Leoni Mollie	Chief Medical Officer	Sep 29 '25	Sale	8.94	12,314	110,114	158,439	Sep 29 07:30 PM
WILSON TROY EDWARD	President and CEO	Sep 29 '25	Sale	8.94	36,615	327,419	246,853	Sep 29 07:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Sep 29 '25	Sale	8.94	4,541	40,607	109,829	Sep 29 07:30 PM
WILSON TROY EDWARD	President & CEO	Sep 08 '25	Buy	8.20	50,000	410,145	100,968	Sep 09 04:28 PM
WILSON TROY EDWARD	President and CEO	Aug 12 '25	Buy	5.85	36,506	213,578	37,474	Aug 14 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 13 '25	Buy	6.64	13,494	89,623	50,968	Aug 14 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 19 '25	Sale	5.96	1,559	9,292	107,948	May 19 06:30 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '25	Sale	6.28	1,558	9,777	21,367	May 19 06:30 PM
FORD KATHLEEN	Officer	May 19 '25	Proposed Sale	5.96	1,558	9,286		May 19 04:06 PM
Hasnain Faheem	Director	Mar 21 '25	Option Exercise	6.32	22,682	143,350	46,665	Mar 24 04:33 PM
Hasnain Faheem	Director	Mar 21 '25	Sale	8.00	22,682	181,456	23,983	Mar 24 04:33 PM
FAHEEM HASNAIN	Director	Mar 21 '25	Proposed Sale	7.85	30,000	235,500		Mar 21 04:21 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 28 '25	Sale	7.87	4,949	38,958	88,193	Jan 28 08:54 PM
Leoni Mollie	Chief Medical Officer	Jan 28 '25	Sale	7.87	4,963	39,068	88,253	Jan 28 08:39 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 28 '25	Sale	7.87	7,281	57,315	107,948	Jan 28 08:38 PM
FORD KATHLEEN	Chief Operating Officer	Jan 28 '25	Sale	7.87	1,817	14,303	21,367	Jan 28 08:38 PM
Burrows Francis	Chief Scientific Officer	Jan 28 '25	Sale	7.87	2,166	17,051	20,705	Jan 28 08:38 PM
Powl Brian T.	Chief Commercial Officer	Jan 28 '25	Sale	7.87	1,583	12,461	59,667	Jan 28 08:38 PM
LEONI MOLLIE	Officer	Jan 28 '25	Proposed Sale	7.77	4,963	38,563		Jan 28 08:37 PM
BAIR TERESA BROPHY	Officer	Jan 28 '25	Proposed Sale	7.77	7,281	56,573		Jan 28 08:37 PM
FORD KATHLEEN	Officer	Jan 28 '25	Proposed Sale	7.77	1,817	14,118		Jan 28 08:37 PM
DOYLE THOMAS JAMES	Officer	Jan 28 '25	Proposed Sale	7.77	4,949	38,454		Jan 28 08:37 PM
BURROWS FRANCIS	Officer	Jan 28 '25	Proposed Sale	7.77	2,166	16,830		Jan 28 08:37 PM
POWL BRIAN T	Officer	Jan 28 '25	Proposed Sale	7.77	1,583	12,300		Jan 28 08:36 PM
FORD KATHLEEN	Chief Operating Officer	Nov 18 '24	Sale	16.03	526	8,434	23,184	Nov 19 04:05 PM
FORD KATHLEEN	Officer	Nov 18 '24	Proposed Sale	15.99	526	8,410		Nov 18 04:03 PM

DNTH

Dianthus Therapeutics Inc

RVMD

Revolution Medicines Inc

CRWV

CoreWeave Inc

APGE

Apogee Therapeutics Inc

KURA

Kura Oncology Inc

Upgrade your FINVIZ experience